KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

Peter E Clark

Eur Urol 90(1) 88

PMID41748387
PMCID-
DOI10.1016/j.eururo.2026.02.006
发表日期2026-02-26
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。